Using a Whole-Person Approach in Supportive Care to Improve Cancer Outcomes

Commentary
Video

The Together for Supportive Cancer Care coalition may advance the national conversation in ensuring comprehensive care for all patients with cancer.

Andrew T. Leitner, MD, spoke with CancerNetwork® regarding the Together for Supportive Cancer Care coalition and how it was designed to take a whole-person care approach that is often missed throughout different treatment strategies.

Leitner, chair in the Department of Supportive Care Medicine, associate clinical professor in the Department of Anesthesiology, and chief in the Division of Interventional Patin Management at City of Hope in Duarte, California, also highlighted that the coalition aims to advance the national conversation surrounding supportive cancer care to impact key factors such as health care utilization and cost-effectiveness of therapy. Emphasizing the possibility of accomplishing “more together,” Leitner expressed his hope in having other partners join the coalition to bring in more focused philanthropic support.

Formed based on the recognition of the insufficiency of current supportive care services, the coalition aims to improve the overall patient experience. Additionally, the coalition aims to share best practices for patients and caregivers to help with the supportive care environment.

Transcript:

What we’re looking to do is advance the comprehensive, whole-person approach to cancer care that we know supportive care provides. This kind of coalition work is greater than the sum of its parts that are limited either to geographies, resource constraints, or smaller constituencies. By coming together to advance the national conversation, we can move some of the metrics by which we are able to provide these services, whether it’s in the payer landscape or recognition of how closely these are tied to outcomes, including health care utilization and cost-effectiveness. We do more together, and this coalition is an example of where we can bring in focused philanthropic support. For that, we have the Biller Family Foundation to thank for bringing us together in this type of forum, as well as increasing buy-in from partner organizations to move this forward. We hope others will join us.

Recent Videos
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
Patients with AML will experience different toxicities based on the treatment they receive, whether it is intensive chemotherapy or targeted therapy.
A younger patient with AML who is more fit may be eligible for different treatments than an older patient with chronic medical conditions.
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Genetic backgrounds and ancestry may hold clues for better understanding pancreatic cancer, which may subsequently mitigate different disparities.
Related Content
Rising cancer diagnoses in the US highlight urgent needs for improved oncology education, workforce distribution, and care infrastructure, especially in rural areas.

A Decline in the US Oncology Workforce: What Will the Next Decade Bring?

Julie M. Vose, MD, MBA
December 2nd 2025
Article

Rising cancer diagnoses in the US highlight urgent needs for improved oncology education, workforce distribution, and care infrastructure, especially in rural areas.

Decision-Making Capacity: The Ethical Core of Patient-Centered Oncology

Decision-Making Capacity: The Ethical Core of Patient-Centered Oncology

Daniel C. McFarland, DO;Louis P. Voigt, MD;Yesne Alici, MD
November 24th 2025
Podcast

Daniel C. McFarland, DO, is joined by Louis P. Voigt, MD, and Yesne Alici, MD, who focused on decision-making capacity and patient-centered care.

PAS-004 was deemed safe and tolerable when given in 37 mg capsules, so the trial will proceed to administer the agent in 45 mg capsules.

Cohort 7 of Novel MEK Inhibitor Trial Completed for MAPK Pathway-Driven Tumors

Tim Cortese
November 25th 2025
Article

PAS-004 was deemed safe and tolerable when given in 37 mg capsules, so the trial will proceed to administer the agent in 45 mg capsules.

Experts discussed supportive care and why it should be integrated into standard oncology care.

How Supportive Care Methods Can Improve Oncology Outcomes

Declan Walsh, MD;Denise B. Reynolds, RD;Adam Friedman, MD, FAAD;Daniel C. McFarland, DO;Michelle Fingeret, PhD;Christian J. Nelson, PhD;William S. Breitbart, MD
November 10th 2025
Podcast

Experts discussed supportive care and why it should be integrated into standard oncology care.

Novel Agent Yields Promising Results in MAPK-Associated Solid Tumors

Novel Agent Yields Promising Results in MAPK-Associated Solid Tumors

Ariana Pelosci
November 21st 2025
Article

Partial responses and stable disease were observed with PAS-004 in patients with advanced solid tumors harboring RAS, NF1, or RAF mutations.

Results from the C-POST trial showed that cemiplimab improved DFS vs placebo in patients with CSCC at high risk of recurrence following surgery and radiation.

EC Approves Adjuvant Cemiplimab in CSCC at High Risk of Recurrence

Tim Cortese
November 20th 2025
Article

Results from the C-POST trial showed that cemiplimab improved DFS vs placebo in patients with CSCC at high risk of recurrence following surgery and radiation.